Wall Street Analysts See a 175.07% Upside in EyePoint Pharmaceuticals (EYPT): Can the Stock Really Move This High?

Shares of EyePoint Pharmaceuticals (EYPT) have gained 12.5% over the past four weeks to close the last trading session at $11.11, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of$30.56 indicates a potential upside of 175.1%.The average comprises nine short-term price targets ranging from a low of $18 to a high of$68, with a standard deviation of $15.13. While the lowest estimat ...